CORT | Jotup

Daniel Tiepelman Joins CORT Events as VP, Operations and Asset Management

Retrieved on:

Tuesday, May 16, 2023

Home Goods, Other Professional Services, Office Products, Other Retail, Specialty, Professional Services, Online Retail, Retail, CORT, Ashley Furniture Industries, Growth, Greater, Marketing, Sales, Management

CORT, the nation’s leading provider of furniture rental and transition services, today announced the appointment of Daniel Tiepelman to the role of vice president of operations and asset management for CORT Events.

Key Points:

CORT, the nation’s leading provider of furniture rental and transition services, today announced the appointment of Daniel Tiepelman to the role of vice president of operations and asset management for CORT Events.
The addition of Tiepelman supports CORT’s executive sales and marketing team and ensures a strong foundation for ongoing excellence in the customer experience.
"We’re pleased to welcome Daniel to the team with his extensive experience across strategic, operational and logistical leadership disciplines,” said Damon Ross, senior group vice president at CORT Events.
He brings 20 years of multi-site management, operations leadership and regional support experience to the CORT Events team, with specific expertise in optimizing systems and processes to deliver premier service while lowering costs.

Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update

Retrieved on:

Wednesday, May 3, 2023

Net income was $15.9 million in the first quarter of 2023 compared to $22.8 million in the same period last year.

Key Points:

Net income was $15.9 million in the first quarter of 2023 compared to $22.8 million in the same period last year.
In April 2023, Corcept purchased 6.6 million shares of its common stock for $145.4 million.
“Korlym is an excellent treatment for patients with Cushing’s syndrome and there are many eligible patients who have yet to receive it.
Corcept holds patents directed to the composition of relacorilant and the use of cortisol modulators, including Korlym, in the treatment of patients with hypercortisolism.

Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call

Retrieved on:

Wednesday, April 26, 2023

CORT, PIN, Communications satellite, Auction

MENLO PARK, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update on May 3, 2023.

Key Points:

MENLO PARK, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update on May 3, 2023.
The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
Participants must register in advance of the conference call by clicking here .
Upon registering, each participant will receive a dial-in number, and a unique access PIN.

Corcept Therapeutics Announces Final Results of Tender Offer

Retrieved on:

Wednesday, April 5, 2023

Transfer, Piper Sandler Companies, CORT, Tax, Mini-tender offer, Therapy, Tender offer, Security (finance), Cryptocurrency, Corcept Therapeutics

In accordance with the terms and conditions of the Tender Offer, based on the final count, Corcept has accepted for purchase 6,610,369 shares of common stock at a purchase price of $22.00 per share, for an aggregate cost of $145,428,118, excluding fees, any excise taxes and expenses relating to the Tender Offer.

Key Points:

In accordance with the terms and conditions of the Tender Offer, based on the final count, Corcept has accepted for purchase 6,610,369 shares of common stock at a purchase price of $22.00 per share, for an aggregate cost of $145,428,118, excluding fees, any excise taxes and expenses relating to the Tender Offer.
The number of shares that Corcept has accepted for purchase in the Tender Offer represents approximately 6 percent of the total number of shares of common stock outstanding as of March 31, 2023.
Corcept had 101,545,296 shares of common stock outstanding following payment for the shares of common stock purchased in the Tender Offer.
This press release is for informational purposes only and is not an offer to buy or the solicitation of an offer to sell any securities of Corcept.

Corcept Therapeutics Announces Preliminary Results of Tender Offer

Retrieved on:

Monday, April 3, 2023

Transfer, Piper Sandler Companies, CORT, Tax, Mini-tender offer, Therapy, Tender, Tender offer, Cryptocurrency, Security (finance), Corcept Therapeutics

In accordance with the terms and conditions of the Tender Offer, based on these preliminary results, Corcept expects to purchase 6,630,151 shares of common stock at a purchase price of $22.00 per share, for an aggregate cost of $145,863,322, excluding fees, any excise taxes and expenses relating to the Tender Offer.

Key Points:

In accordance with the terms and conditions of the Tender Offer, based on these preliminary results, Corcept expects to purchase 6,630,151 shares of common stock at a purchase price of $22.00 per share, for an aggregate cost of $145,863,322, excluding fees, any excise taxes and expenses relating to the Tender Offer.
The number of shares that Corcept expects to purchase in the Tender Offer represents approximately 6 percent of the total number of shares of common stock outstanding as of March 30, 2023.
Corcept expects to have 101,435,180 shares of common stock outstanding immediately following payment for the shares of common stock purchased in the Tender Offer.
This press release is for informational purposes only and is not an offer to buy or the solicitation of an offer to sell any securities of Corcept.

CORT Survey Reveals Rising Interest in Furniture Rental: 77% of Movers Want Furnished Apartments

Retrieved on:

Thursday, April 13, 2023

Home Goods, Construction & Property, Millennials, Baby Boomers, Consumer, Generation Z, Retail, Residential Building & Real Estate, Baby boomers, CORT, Street Hassle, Travel, Renting

The annual survey, which polled 5,000 respondents ages 18-65+, marks the third consecutive year CORT has conducted this study.

Key Points:

The annual survey, which polled 5,000 respondents ages 18-65+, marks the third consecutive year CORT has conducted this study.
In 2023, results showed the greatest interest in renting furnished apartments among those ages 25-34 (84%) and 35-44 (85%) followed by ages 18-24 and 45-54 (77%).
As the survey findings indicate, choosing furnished apartments is attractive for a variety of reasons.
Furnished apartments can offer fully equipped living spaces for rent that offer convenience, cost-effectiveness, and flexibility.

CORT Wins CHPA Associate Partner of the Year Award

Retrieved on:

Thursday, April 6, 2023

CORT, the nation’s leading provider of furniture rental and transition services, was recently awarded the Corporate Housing Providers Association (CHPA) 2023 Tower of Excellence Award for Associate Partner of the Year.

Key Points:

CORT, the nation’s leading provider of furniture rental and transition services, was recently awarded the Corporate Housing Providers Association (CHPA) 2023 Tower of Excellence Award for Associate Partner of the Year.
The award recognizes CORT’s commitment to service and excellence in the industry and the support they deliver to CHPA provider and agency members.
Jeff has served on the CHPA Board of Directors since 2020 and will continue serving for the next three years.
Additionally, CORT demonstrated its dedication to CHPA members throughout 2022 by increasing in-person visits with an expanding sales team.

Corcept Therapeutics Initiates CATALYST Clinical Trial

Retrieved on:

Tuesday, March 28, 2023

Doctor of Pharmacy, Depression, Prevalence, Diabetes, Anxiety, Type 2 diabetes, Syndrome, Neck, Corcept Therapeutics, Patient, Physician, CORT, Ageing, Irritability, Fatigue, Pharmaceutical industry

“We are excited that our CATALYST trial is now open,” said Bill Guyer, PharmD, Corcept’s Chief Development Officer.

Key Points:

“We are excited that our CATALYST trial is now open,” said Bill Guyer, PharmD, Corcept’s Chief Development Officer.
The most prominent diabetologists in the United States helped us design and are participating in CATALYST, which will be the largest study of its kind ever to be conducted.
Data from CATALYST will enable physicians to better identify and care for these patients.
Corcept holds patents directed to the composition of relacorilant and the use of cortisol modulators, including Korlym, in the treatment of patients with hypercortisolism.

CORT Events Welcomes New VP of Sales & Marketing, Phil DeSarno

Retrieved on:

Tuesday, March 21, 2023

Interior Design, Online Retail, Retail, Home Goods, Residential Building & Real Estate, Construction & Property, Office Products, CORT, Communication, Marketing, Sales, Management

“CORT Events will continue to innovate our business and expand our strategic and operational capabilities.

Key Points:

“CORT Events will continue to innovate our business and expand our strategic and operational capabilities.
Adding Phil to our team is a significant step forward for our organization and the service that we provide to our clients.”
CORT Events welcomes DeSarno in the newly created role of Vice President of sales, marketing, and merchandising.
DeSarno, who previously served as assistant vice president of a rental manufacturer business at Enterprise Holding Inc., joins CORT Events with over 27 years of experience in strategic sales where he led teams across multiple divisions, helping to facilitate both profitable growth and revenue.
As VP of sales, marketing, and merchandising, DeSarno will be responsible for enhancing divisional relationships and alignment with CORT’s top clients to drive business development, while boosting CORT’s brand image, and ensuring that sales, marketing, and merchandising are in supportive alignment.

Corcept Therapeutics Announces Commencement of Tender Offer to Purchase up to 7,500,000 Shares of its Common Stock

Retrieved on:

Monday, March 6, 2023

Transfer, Therapy, CORT, Piper Sandler Companies, Letter, Cryptocurrency, Security (finance), Corcept Therapeutics

The closing price of the Shares on The Nasdaq Stock Market on March 3, 2023, the last full trading day before the start of the tender offer, was $19.20 per Share.

Key Points:

The closing price of the Shares on The Nasdaq Stock Market on March 3, 2023, the last full trading day before the start of the tender offer, was $19.20 per Share.
The tender offer is scheduled to expire one minute after 11:59 P.M., New York City Time, March 31, 2023, unless the offer is extended or terminated.
The tender offer is also subject to terms and conditions, which are described in detail in the offer to purchase.
King & Co., Inc. is serving as the information agent for the tender offer and Continental Stock Transfer & Trust Company is serving as the depositary.